- Home
- IQ vs ANIP Comparison
IQ vs ANIP Comparison
Compare IQ & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IQ
- ANIP
- Stock Information
- Founded
- IQ 2009
- ANIP 2001
- Country
- IQ China
- ANIP United States
- Employees
- IQ N/A
- ANIP N/A
- Industry
- IQ Consumer Electronics/Video Chains
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- IQ Consumer Discretionary
- ANIP Health Care
- Exchange
- IQ Nasdaq
- ANIP Nasdaq
- Market Cap
- IQ 1.6B
- ANIP 1.4B
- IPO Year
- IQ 2018
- ANIP N/A
- Fundamental
- Price
- IQ $1.98
- ANIP $66.30
- Analyst Decision
- IQ Hold
- ANIP Strong Buy
- Analyst Count
- IQ 5
- ANIP 9
- Target Price
- IQ $2.60
- ANIP $80.56
- AVG Volume (30 Days)
- IQ 18.6M
- ANIP 277.5K
- Earning Date
- IQ 08-21-2025
- ANIP 08-05-2025
- Dividend Yield
- IQ N/A
- ANIP N/A
- EPS Growth
- IQ N/A
- ANIP N/A
- EPS
- IQ 0.04
- ANIP N/A
- Revenue
- IQ $3,925,356,854.00
- ANIP $674,068,000.00
- Revenue This Year
- IQ $2.04
- ANIP $30.84
- Revenue Next Year
- IQ $3.29
- ANIP $7.39
- P/E Ratio
- IQ $48.87
- ANIP N/A
- Revenue Growth
- IQ N/A
- ANIP 30.27
- 52 Week Low
- IQ $1.50
- ANIP $52.50
- 52 Week High
- IQ $3.76
- ANIP $77.00
- Technical
- Relative Strength Index (RSI)
- IQ 73.98
- ANIP 55.06
- Support Level
- IQ $1.77
- ANIP $63.60
- Resistance Level
- IQ $1.92
- ANIP $66.97
- Average True Range (ATR)
- IQ 0.08
- ANIP 2.01
- MACD
- IQ 0.02
- ANIP 0.10
- Stochastic Oscillator
- IQ 90.54
- ANIP 57.64
About IQ iQIYI Inc.
Iqiyi is a leading streaming video-on-demand company in China that generates revenue mostly through a subscription basis. The platform also provides user-generated content to nonpaying users, monetized through ads. The company self-produces much of the subscription content and also generates revenue through content distribution, gaming, and IP licensing. Iqiyi competes directly with Tencent Video, Alibaba's Youku, ByteDance's MangoTV, and Bilibili. The company is 45% and 5% owned by Baidu and Xiaomi, respectively.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.